Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
ASCO 2024 – Blenrep “should return” to the US
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
